Optiscan secures $17.75m to fund strategic transformation

Optiscan Imaging Ltd (ASX:OIL) announced the successful issuance of 208,835,829 fully paid ordinary shares, raising a total of $17,751,045.47 through its pro-rata renounceable entitlement offer. The offer, which closed on September 16, 2025, is intended to fund the company's strategic transformation into a medical device manufacturer and digital healthcare solution provider.

The funds raised include $9,809,000.85 from entitlements applied for through the offer, corresponding to 115,400,004 shares. An additional $155,768.61 was raised from shares applied for by eligible shareholders through the shortfall, accounting for 1,832,572 shares.

The remaining shortfall, totaling $7,786,276.51, was allocated to the underwriter, representing 91,603,253 shares. The company’s innovative technology aims to provide super high-resolution digital pathology images for cancer diagnosis and surgical treatment, enabling real-time insights during medical procedures and research.